Biocon
Siddharth Mittal is a seasoned executive with extensive experience in finance and corporate leadership. Currently serving as the Managing Director and Chief Executive Officer at Biocon, Siddharth has also held key positions including President and Chief Financial Officer, and Vice President of Finance. Prior to Biocon, Siddharth served as Vice President of Finance and Corporate Controller at Symphony Teleca Corporation and was the Chief Financial Officer for the U.S. BPO Division at Cambridge Solutions Limited. Siddharth's career began at S. R. Batliboi & Co. LLP as a Chartered Accountant. Siddharth is also a Certified Public Accountant and a member of The Institute of Chartered Accountants of India.
Biocon
21 followers
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company's brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.